NF1 and neurofibromatosis type 1: In view of the rationale that NF1 is likely to be driven through inappropriate Ras activation, the FTI tipifarnib was tested in phase II clinical trial for pediatric NF1 patients with progressive plexiform neurofibromas, but positive responses have not been reported.